# Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

> **NCT03615924** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 193 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Ticagrelor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03615924
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-26
- **Primary completion:** 2020-08-13
- **Final completion:** 2020-08-13
- **Target enrollment:** 193 (ACTUAL)
- **Why stopped:** Recommendation from an independent data monitoring committee (DMC) and accepted by AstraZeneca.
- **Last updated:** 2021-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03615924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03615924, "Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03615924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*